Corcept Therapeutics Stock Soars 82% On Positive Phase 3 Trial Results

(RTTNews) - Corcept Therapeutics Inc. (CORT) is trading at $102.73, up 82.88 percent or $45.28 during Monday's trading, after announcing that its pivotal Phase 3 trial, ROSELLA, met its primary endpoint.

The stock opened at $94.72 and has traded between $87.58 and $104.73 so far, compared to a previous close of $54.63 on the Nasdaq. Trading volume has surged to 9.62 million shares, far exceeding the average of 1.01 million. Its 52-week range now stands at $20.84 to $104.73.

The study demonstrated that relacorilant plus nab-paclitaxel significantly improved progression-free survival in patients with platinum-resistant ovarian cancer, as assessed by blinded independent central review.